School of Medicine


Showing 101-120 of 126 Results

  • Kuldev Singh, MD, MPH

    Kuldev Singh, MD, MPH

    Professor of Ophthalmology

    Current Research and Scholarly InterestsGlaucoma, clinical epidemiology

  • Stephen Smith, MD

    Stephen Smith, MD

    Clinical Assistant Professor, Ophthalmology

    Current Research and Scholarly InterestsRESEARCH OVERVIEW

    Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.


    INNOVATION HIGHLIGHTS

    In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.

    Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course.

  • Gayathri Srinivasan OD, MS

    Gayathri Srinivasan OD, MS

    Clinical Associate Professor, Ophthalmology

    BioDr. Srinivasan is a Clinical Associate Professor in the Department of Ophthalmology at Stanford University. Her clinical focus is in the management of concussion-related vision disorders. Dr. Srinivasan's research interests are amblyopia, strabismus, and concussion-related vision disorders. She serves as an investigator for ongoing clinical studies in the Vision Development and Oculomotor lab headed by Dr. Tawna Roberts.

  • Creed Stary

    Creed Stary

    Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult MSD) and, by courtesy, of Ophthalmology

    Current Research and Scholarly InterestsMechanisms promoting neuronal survival following cerebral ischemia-reperfusion injury; utilizing microRNA's to target multiple pathways to promote mitochondrial homeostasis and cell survival; anesthetic neurotoxicity; astrocyte-neuronal interaction

  • Yang Sun, MD, PhD

    Yang Sun, MD, PhD

    Professor of Ophthalmology

    Current Research and Scholarly InterestsWe are interested in the role of inositol phosphatases in eye development and disease, using both animal models and human disease tissue. We are a translational laboratory seeking to understand the basic function of proteins as well as developing therapeutic strategies for clinical trials.

  • Christopher N. Ta, MD

    Christopher N. Ta, MD

    Professor of Ophthalmology

    BioChristopher N. Ta, MD specializes in the diagnosis and medical treatment of cornea diseases. His areas of expertise are in the treatment of ocular infections, inflammation, dry eyes and ocular surface diseases. He has conducted numerous clinical trials toward the prevention and treatment of ocular infections. Dr. Ta also has extensive clinical experience in the treatment of ocular graft-versus host disease following hematopoietic stem cell transplantation.

  • Geoffrey Craig Tabin, MD

    Geoffrey Craig Tabin, MD

    Fairweather Foundation Professor

    BioDr. Geoff Tabin is Co-Founder and Chairman of the Himalayan Cataract Project and a Professor of Ophthalmology and Global Medicine at Stanford University. He has published more than 45 peer-reviewed articles, two books and a dozen book chapters related to his work in ophthalmology and the developing world.

    Dr. Tabin is the fourth person in the world to reach the tallest peak on each of the seven continents. His passion for mountain climbing directed him to his professional career in eye care. After summiting Mt. Everest, on one of his expeditions, he came across a Dutch team performing cataract surgery on a woman who had been needlessly blind for three years. It was then he understood his life calling.

    Tabin graduated from Yale University and then earned an MA in Philosophy at Oxford University on a Marshall Scholarship. From there, he took his interest in moral philosophy and health care delivery to Harvard Medical School where he earned his MD in 1985. After completing an ophthalmology residency at Brown University and a fellowship in corneal surgery in Melbourne, Australia, Dr. Tabin returned to Nepal to work with Dr. Sanduk Ruit.

    Tabin and Nepalese eye surgeon Dr. Sanduk Ruit established the Himalayan Cataract Project in 1995 – with a vow to work to eliminate all preventable and treatable blindness from the Himalayan region in their lifetime, a goal, in Tabin’s words, “more audacious than setting out to make the first assent of the East Face of Mount Everest.” Dr. Ruit, whom the Associated Press heralded as the “god of sight” to the world’s poor, and Tabin have proven that hospital quality standards can be applied in impoverished areas devoid of electricity and clean water. Their successful approach to restoring sight and dogged perseverance has made possible what 20 years ago seemed impossible.

    The Himalayan Cataract Project has since expanded beyond the Himalayas to encompass Sub-Saharan Africa as well. Dr.Tabin spends a considerable part of the year working abroad throughout the Himalayas and Sub-Saharan Africa. At Stanford his practice focus encompasses surgery and treatment of diseases of the anterior and external eye including cataract and corneal surgery.

  • Douglas Vollrath

    Douglas Vollrath

    Professor of Genetics and, by courtesy, of Ophthalmology

    Current Research and Scholarly InterestsThe Vollrath lab works to uncover molecular mechanisms relevant to the health and pathology of the outer retina. We study metabolic and other cellular interactions between the glial-like retinal pigment epithelium (RPE) and adjacent photoreceptors, with the goals of understanding the pathogenesis of photoreceptor degenerative diseases such as age-related macular degeneration and retinitis pigmentosa, and developing therapies.

  • Brian A. Wandell

    Brian A. Wandell

    Isaac and Madeline Stein Family Professor and Professor, by courtesy, of Electrical Engineering, of Ophthalmology and at the Graduate School of Education

    Current Research and Scholarly InterestsModels and measures of the human visual system. The brain pathways essential for reading development. Diffusion tensor imaging, functional magnetic resonance imaging and computational modeling of visual perception and brain processes. Image systems simulations of optics and sensors and image processing. Data and computation management for reproducible research.

  • Sophia Y. Wang, MD, MS

    Sophia Y. Wang, MD, MS

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsI use and integrate a wide variety of data sources in my research, spanning both structured and unstructured forms, including national survey datasets, health insurance claims data, patient generated online text, surgical video, and electronic health records. I investigate outcomes of treatments for glaucoma and cataract, as well as other areas of ophthalmology. My focus is on developing artificial intelligence methods to predict ophthalmology outcomes.

  • Sui Wang, PhD

    Sui Wang, PhD

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.

    1. Investigating retinal development:
    We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.

    2. Understanding diabetes-induced cell-type-specific responses in the retina:
    Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.

    3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
    Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo.